BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of …PR Newswire (press release)The company also announced that the New England Journal of Medicine (NEJM) published an independent, peer-reviewed… Continue reading
Medical Xpress |
Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma
Cancer Network A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I (abstract 740) study presented at the … CAR T, immunotherapy bring new hope for multiple myeloma patientsMedical Xpress ‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma studyReuters #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News |
|
ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression
GlobeNewswire (press release) SEOUL, South Korea, Dec. 11, 2017 (GLOBE NEWSWIRE) — ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced data demonstrating that the Company’s CRISPR/Cas9 gene editing platform can target and disrupt … |
Endpoints News |
#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky
Endpoints News Following up on its impressive work on a new gene therapy for hemophilia B, Spark Therapeutics $ONCE has offered a peek at its cards on the early data from a separate program it has on hemophilia A. And it’s clear that there’s a lot of work to be done … ASH17: Spark gene therapy falls behind BioMarin in hemophiliaBioPharma Dive Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial ShowsHemophilia News Today This Bull Is Sticking By Spark Therapeutics Inc (ONCE) and Its Novel …Smarter Analyst Zacks Investment Research –SEC.gov all 115 news articles » |